Ligand Pharmaceuticals Incorporated (LGND)

Receivables turnover

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Revenue (ttm) US$ in thousands 167,133 152,422 133,478 118,313 131,314 153,595 186,815 217,868 219,582 241,673 240,420 267,676 277,133 274,650 251,663 208,408 186,419 143,432 126,392 109,959
Receivables US$ in thousands — — — — — — — — — — — — — — — — — — — —
Receivables turnover — — — — — — — — — — — — — — — — — — — —

December 31, 2024 calculation

Receivables turnover = Revenue (ttm) ÷ Receivables
= $167,133K ÷ $—K
= —

The receivables turnover ratio for Ligand Pharmaceuticals Incorporated is not available for the periods stated in the provided data. A receivables turnover ratio is a measure of a company's efficiency in collecting outstanding credit balances from its customers during a specific period. It indicates how many times a company collects its average accounts receivable balance during a certain time frame.

Since the receivables turnover values are marked as "—", this suggests that specific data related to accounts receivable turnover for Ligand Pharmaceuticals Incorporated is not disclosed, not applicable, or not calculated based on the available financial information. This absence of information makes it challenging to assess the effectiveness of Ligand Pharmaceuticals' credit and collections policies and its ability to efficiently manage its receivables.

As a financial analyst, it's important to note that a higher receivables turnover ratio generally signifies a more efficient collection process and effective credit granting policies, while a lower ratio may suggest potential issues with collecting receivables in a timely manner or with credit quality.

It would be advisable to consult additional financial statements or disclosures from the company to obtain a comprehensive understanding of Ligand Pharmaceuticals' receivables turnover performance and to gain further insights into its accounts receivable management practices.